PHERGain

orange__line

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study.

The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response (pCR) in the breast and axilla.

And also assess 3-year invasive disease-free survival (iDFS) in patients with HER2-positive (HER: human epidermal receptor) breast cancer treated with neoadjuvant trastuzumab and pertuzumab (± endocrine therapy) using a FDG-PET response-adapted strategy.

NAME TUMOR TYPE TITLE PHASE N SITES COUNTRY STATUS
PHERGain
HER2+ EBC Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast II 400 59 Spain, Portugal, France, UK, Italia, Belgium, Germany Actively enrolling patients

SABCS 2017 – Download the abstract

Botón CONTACT US